PerkinElmer Gets Ready for Its Largest Deal Ever

PerkinElmer just announced a deal that, if all goes according to plan, will be the company's largest transaction to date at $5.25 billion.

The acquisition target is BioLegend, a private company that provides academic and biopharmaceutical customers with antibodies and reagents in high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing. The deal is expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary closing conditions.